课题基金 / 基金详情

TELOMERASES AND TELOMERASE MOLECULAR BIOLOGY

TELOMERASES AND TELOMERASE MOLECULAR BIOLOGY
端粒酶和端粒酶分子生物学
批准号:
6396863
负责人:
BRAD E. WINDLE
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-30 至 2001-09-29

项目摘要

项目成果

BRAD E. WINDLE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Telomeres have a G-rich repeated DNA sequence that maintains chromosome end stability. Telomerase is a reverse transcriptase-like ribonucleoprotein that maintains the telomere sequence. Telomerase is expressed in the majority of tumor cells but not in normal cells. Telomerase and telomeres are ideal tumor-specific targets for anti-cancer therapeutic strategies. Our preliminary studies show the discovery of the first telomerase inhibitors. Our studies also show that telomerase inhibitors induce telomere shortening, chromosome end fusion, and eventually cell death. Cells have shown the ability to adapt to telomerase inhibition. The goals of this proposal are to l) elucidate the molecular structure of telomerase and provide a more defined target for our anti-cancer strategies, and 2) determine the mechanism(s) of cellular adaptation to telomerase inhibitors. These goals will be accomplished by mapping and cloning the genes for the telomerase proteins and RNA template. Through our collaboration with Program l, purified telomerase will be used as a source of purified telomerase RNA for cloning. Somatic cell genetics will be used to map the telomerase activity. The new technique of Differential Display will be used to detect mRNAs expressed in posttelomerase-activated cells that are not expressed in pre-telomerase activated cells. The mapping will be coordinated with the isolation of candidate cDNA clones for the proteins and RNA to accelerate the identification of legitimate clones. The cDNA clones of the RNA will be screened for appropriate template sequence, secondary structure, and ability to direct in vitro and in vivo telomerase activity. The cDNAs for telomerase proteins will be expressed for production of antibodies. The antibodies and DNA clones will serve as probes for use in studies of telomerase expression in Program 3 and in tumor specimens from Program 4. The data from these studies will be used by Program 2 for structure modeling and specific drug design. Potential telomerase inhibitors, such as anti RNA oligonucleotides will be studied by Program l. The mechanism of adaptation to telomerase inhibitors will also be studied. Hypotheses concerning drug metabolism, telomerase up-regulation and telomerase specificity will be tested.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Structures of the Human Papilloma Virus Genome in HNSCC
  • 批准号:
    9332364
  • 项目类别:
  • 资助金额:
    $22.88万
  • 财政年份:
    2016
  • 负责人:
    BRAD E. WINDLE
  • 依托单位:
Novel Structures of the Human Papilloma Virus Genome in HNSCC
  • 批准号:
    9166448
  • 项目类别:
  • 资助金额:
    $22.88万
  • 财政年份:
    2016
  • 负责人:
    BRAD E. WINDLE
  • 依托单位:
HTERT EXPRESSION AS A MARKER FOR EARLY CANCER DETECTION
  • 批准号:
    6378217
  • 项目类别:
  • 资助金额:
    $10.88万
  • 财政年份:
    2000
  • 负责人:
    BRAD E. WINDLE
  • 依托单位:
HTERT EXPRESSION AS A MARKER FOR EARLY CANCER DETECTION
  • 批准号:
    6317199
  • 项目类别:
  • 资助金额:
    $10.88万
  • 财政年份:
    2000
  • 负责人:
    BRAD E. WINDLE
  • 依托单位:
国内基金
海外基金
免标记CRISPR-RNA适配体与门逻辑分子诊断新方法研究
  • 批准号:
    2026JJ50010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    应站明
  • 依托单位:
RNA m6A修饰通过调控FDX1介导的铜死亡参与补阳还五汤抗脑缺血再灌注损伤作用机制的研究
  • 批准号:
    2026JJ81091
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    刘亮
  • 依托单位:
基于合成生物标志物的超多重RNA数字化检测平台用于肿瘤精准诊断和分期评估
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    程子译
  • 依托单位:
Dead-box解旋酶DDX23通过调控RNA高级结构促进肝癌细胞恶性生物学行为的分子机制研究
  • 批准号:
    JCZRLH202600588
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位: